These mutations enhance the trimethylating activity of PRC2, leading to alterations in the epigenomic landscape and transcriptional profiles, and even reorganization of chromatin domains.[3, 4, 5, 6, 7] Expression of Ezh2Y641F in B cells or melanocytes has been shown to result in high‐penetrance lymphoma or melanoma in mice,[8, 9] providing further evidence of the oncogenic nature of these EZH2 GoF mutations. This evidence concerns the gene EZH2 and lymphoma.